Terms ending in 2027
Every in-force patent on Eagle Pharmaceuticals, Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US D676,572 | Vial with Collar Label In force · High confidence | Eagle Pharmaceuticals, Inc. | In force | High confidence | |
| US 7,589,106 | Alcohol Free Formulation of Argatroban In force · Medium confidence | Eagle Pharmaceuticals, Inc. | In force | Medium confidence | |
| US 7,687,516 | Alcohol Free Formulation of Argatroban In force · Medium confidence | Eagle Pharmaceuticals, Inc. | In force | Medium confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.